{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:08:29Z","timestamp":1793725709586,"version":"4.6.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jconrel.2023.02.029","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T17:23:10Z","timestamp":1678468990000},"page":"360-372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Nanodrug removes physical barrier to promote T-cell infiltration for enhanced cancer immunotherapy"],"prefix":"10.1016","volume":"356","author":[{"given":"Zecong","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liteng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintao","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangshun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.02.029_bb0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12929-017-0329-9","article-title":"Cancer immunotherapies targeting the PD-1 signaling pathway","volume":"24","author":"Iwai","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0010","doi-asserted-by":"crossref","first-page":"8541","DOI":"10.1002\/jcp.27816","article-title":"Immune checkpoint blockade opens a new way to cancer immunotherapy","volume":"234","author":"Sadreddini","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0015","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0020","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2023.02.029_bb0025","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2023.02.029_bb0030","article-title":"Immunotherapy: breaching the barriers for cancer treatment","volume":"374","author":"Martinez","year":"2019","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0035","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrc1456","article-title":"High interstitial fluid pressure - an obstacle in cancer therapy","volume":"4","author":"Heldin","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2023.02.029_bb0040","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","article-title":"Concepts of extracellular matrix remodelling in tumour progression and metastasis","volume":"11","author":"Winkler","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.574276","article-title":"Immunomodulatory role of the extracellular matrix within the liver disease microenvironment","volume":"11","author":"McQuitty","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0050","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1172\/JCI45817","article-title":"Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors","volume":"122","author":"Salmon","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0055","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/2159-8290.CD-11-0136","article-title":"Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look","volume":"1","author":"Whatcott","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0060","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2023.02.029_bb0065","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2019.1670893","article-title":"Degradation of tumour stromal hyaluronan by small extracellular vesicle-PH20 stimulates CD103(+) dendritic cells and in combination with PD-L1 blockade boosts anti-tumour immunity","volume":"8","author":"Hong","year":"2019","journal-title":"J. Extracell Vesicles"},{"key":"10.1016\/j.jconrel.2023.02.029_bb0070","first-page":"963","article-title":"Folic acid-modified exosome-PH20 enhances the efficiency of therapy via modulation of the tumor microenvironment and directly inhibits tumor cell metastasis","volume":"6","author":"Feng","year":"2021","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0075","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1158\/1078-0432.CCR-15-2010","article-title":"Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer","volume":"22","author":"Hingorani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0080","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1359-6101(01)00032-6","article-title":"Interleukin-12 in anti-tumor immunity and immunotherapy","volume":"13","author":"Colombo","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41434-018-0044-5","article-title":"Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy","volume":"26","author":"Mukhopadhyay","year":"2019","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0090","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11010-016-2687-0","article-title":"Interleukin-12 inhibits the hepatocellular carcinoma growth by inducing macrophage polarization to the M1-like phenotype through downregulation of Stat-3","volume":"415","author":"Wang","year":"2016","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0095","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.3390\/ma3031928","article-title":"Targeted delivery of protein drugs by Nanocarriers","volume":"3","author":"Solaro","year":"2010","journal-title":"Materials (Basel)"},{"key":"10.1016\/j.jconrel.2023.02.029_bb0100","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.leukres.2009.01.020","article-title":"Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the eastern cooperative oncology group","volume":"33","author":"Lacy","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0105","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1089\/107999001750169934","article-title":"Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma","volume":"21","author":"Motzer","year":"2001","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0110","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2023.02.029_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090116","article-title":"Abrogation of TNF\u03b1 production during cancer immunotherapy is crucial for suppressing side effects due to the systemic expression of IL-12","volume":"9","author":"Barrios","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.02.029_bb0120","first-page":"76","article-title":"Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses","volume":"9","author":"Portielje","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0125","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","volume":"14","author":"Calabrese","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0130","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"Bmj"},{"key":"10.1016\/j.jconrel.2023.02.029_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120636","article-title":"Nanodrug with dual-sensitivity to tumor microenvironment for immuno-sonodynamic anti-cancer therapy","volume":"269","author":"Huang","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.02.029_bb0140","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/anie.201509507","article-title":"Facile generation of tumor-pH-labile linkage-bridged block copolymers for chemotherapeutic delivery","volume":"55","author":"Sun","year":"2016","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0145","doi-asserted-by":"crossref","first-page":"12845","DOI":"10.1021\/acsami.0c20422","article-title":"Dual-sensitive PEG-Sheddable Nanodrug hierarchically incorporating PD-L1 antibody and zinc Phthalocyanine for improved Immuno-photodynamic therapy","volume":"13","author":"Su","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2023.02.029_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201906832","article-title":"Codelivery of anti-PD-1 antibody and paclitaxel with matrix metalloproteinase and pH dual-sensitive micelles for enhanced tumor Chemoimmunotherapy","volume":"16","author":"Su","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2023.02.029_bb0155","doi-asserted-by":"crossref","first-page":"43493","DOI":"10.1021\/acsami.8b17684","article-title":"Collagenase-encapsulated pH-responsive nanoscale coordination polymers for tumor microenvironment modulation and enhanced photodynamic nanomedicine","volume":"10","author":"Liu","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2023.02.029_bb0160","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.3390\/ijms22136995","article-title":"Macrophage polarization states in the tumor microenvironment","volume":"22","author":"Boutilier","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0165","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3389\/fonc.2015.00192","article-title":"Breaching the castle walls: Hyaluronan depletion as a therapeutic approach to Cancer therapy","volume":"5","author":"Shepard","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0170","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1021\/am100641z","article-title":"Water-soluble MnO nanocolloid for a molecular T1 MR imaging: a facile one-pot synthesis, in vivo T1 MR images, and account for relaxivities","volume":"2","author":"Baek","year":"2010","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2023.02.029_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119600","article-title":"Differential characterization of hepatic tumors in MR imaging by burst-released Mn(2+)-ions from hollow manganese-silicate nanoparticles in the liver","volume":"230","author":"Kim","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.02.029_bb0180","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay7785","article-title":"Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-\u03baB inhibitor for antitumor immunotherapy","volume":"6","author":"Xiao","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0185","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/jps.22054","article-title":"Delivery of therapeutic proteins","volume":"99","author":"Pisal","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0190","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/j.1745-7254.2005.00216.x","article-title":"Body distribution and in situ evading of phagocytic uptake by macrophages of long-circulating poly (ethylene glycol) cyanoacrylate-co-n-hexadecyl cyanoacrylate nanoparticles","volume":"26","author":"Huang","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0195","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jconrel.2006.06.017","article-title":"PEG-modified gold nanorods with a stealth character for in vivo applications","volume":"114","author":"Niidome","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.029_bb0200","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-11-3114","article-title":"The pancreas cancer microenvironment","volume":"18","author":"Feig","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0205","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00441-009-0841-7","article-title":"Extracellular matrix genes as hypoxia-inducible targets","volume":"339","author":"Myllyharju","year":"2010","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.08.017","article-title":"Extracellular matrix remodeling regulates glucose metabolism through TXNIP destabilization","volume":"175","author":"Sullivan","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2023.02.029_bb0215","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1038\/s41467-022-31141-6","article-title":"Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-\u03b2 degradation","volume":"13","author":"Shen","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2020.102157","article-title":"Biodegradable calcium phosphate nanoparticles for cancer therapy","volume":"279","author":"Khalifehzadeh","year":"2020","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.67","article-title":"Interferon-\u03b3 derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity","volume":"8","author":"Bhat","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0230","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fimmu.2018.00293","article-title":"Regulation of human natural killer cell IFN-\u03b3 production by MicroRNA-146a via targeting the NF-\u03baB signaling pathway","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2023.02.029_bb0235","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.immuni.2009.09.002","article-title":"Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases","volume":"31","author":"Hu","year":"2009","journal-title":"Immunity"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923001414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923001414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:40:00Z","timestamp":1759164000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923001414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":47,"alternative-id":["S0168365923001414"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.02.029","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanodrug removes physical barrier to promote T-cell infiltration for enhanced cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.02.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}